| Downstream administration of a high-dose tirofiban bolus in high-risk patients with unstable angina undergoing early percutaneous coronary intervention. | |
| | |
MedLine Citation:
|
PMID: 16412804 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: The best treatment option for high-risk patients with unstable coronary syndrome is an early invasive strategy accompanied by intensive anti-platelet therapy. We tested the effect on clinical outcome of early coronary angioplasty using a high-dose bolus of tirofiban in patients with non-ST segment elevation acute coronary syndrome. METHODS: One hundred and forty consecutive patients with unstable coronary syndrome who underwent an immediate percutaneous coronary intervention with the administration of a high (25 microg/kg) dose bolus of tirofiban followed by an 18-h infusion of 0.15 microg kg(-1) min(-1) were compared with a matched control group of 162 patients treated with abciximab. The primary endpoint of the study was the 30-day incidence of major adverse cardiac events; the secondary endpoints were the incidence of major and minor bleeding. RESULTS: The time from admission to PCI was slightly shorter in the tirofiban group (3.9+/-4.8 vs. 4.5+/-4.4 h; P=0.26). The 30-day rate of major adverse cardiac events was similar in the two groups (6% with tirofiban and 8.6% with abciximab: OR=1.37, 95% CI=0.58-3.29, P=0.52). No major bleeding episodes were observed; the incidence of minor bleeding was 3.6% in the tirofiban group and 2.5% in the abciximab group (OR=0.68, 95% CI=0.18-2.59, P=0.74). CONCLUSIONS: In this preliminary study, the beneficial effect of the administration of a high-dose tirofiban bolus on 30-day clinical outcomes was similar to that of abciximab in high-risk patients with unstable angina undergoing immediate percutaneous coronary intervention. The results of this therapeutic strategy should be tested in a larger randomised study. |
| | |
Authors:
|
Gian B Danzi; Marco Sesana; Cinzia Capuano; Luigi Mauri; Simonetta Predolini; Roberto Baglini |
Related Documents
:
|
23438784 - Centrifugal continuous-flow left ventricular assist device in patients with hypertrophi... 23022304 - Differentiation between left bundle branch block and left ventricular hypertrophy: impl... 23740694 - Epidural analgesia for cardiac surgery. 23099984 - The heart: a symbol from ancient times to current biomedics. 8682114 - Cytometric analysis of ventricular myocyte nuclei in idiopathic dilated cardiomyopathy:... 23601374 - Panmedullary edema with inferior olivary hypertrophy in bilateral medial medullary infa... |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: International journal of cardiology Volume: 107 ISSN: 0167-5273 ISO Abbreviation: Int. J. Cardiol. Publication Date: 2006 Feb |
Date Detail:
|
Created Date: 2006-01-17 Completed Date: 2006-09-12 Revised Date: 2013-05-24 |
Medline Journal Info:
|
Nlm Unique ID: 8200291 Medline TA: Int J Cardiol Country: Ireland |
Other Details:
|
Languages: eng Pagination: 241-6 Citation Subset: IM |
Affiliation:
|
Catheterisation Laboratory, Casa di Cura Poliambulanza Hospital, Via Bissolati 57, 25124 Brescia, Italy. gbdanzi@mail.com |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Aged Angina, Unstable / blood, radiography, therapy* Angioplasty, Balloon, Coronary* / adverse effects Antibodies, Monoclonal / administration & dosage Biological Markers / blood Case-Control Studies Confounding Factors (Epidemiology) Coronary Angiography Disease-Free Survival Dose-Response Relationship, Drug Electrocardiography Female Follow-Up Studies Humans Immunoglobulin Fab Fragments / administration & dosage Male Middle Aged Platelet Aggregation Inhibitors / administration & dosage* Platelet Glycoprotein GPIIb-IIIa Complex / antagonists & inhibitors Prospective Studies Risk Factors Time Factors Treatment Outcome Tyrosine / administration & dosage, analogs & derivatives* |
| Chemical | |
Reg. No./Substance:
|
0/Antibodies, Monoclonal; 0/Biological Markers; 0/Immunoglobulin Fab Fragments; 0/Platelet Aggregation Inhibitors; 0/Platelet Glycoprotein GPIIb-IIIa Complex; 144494-65-5/tirofiban; 55520-40-6/Tyrosine; X85G7936GV/abciximab |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Sudden death is less common than might be expected in underprivileged ethnic minorities at high card...
Next Document: Determinants of model of renarrowing after beta radiation for in-stent restenosis.